The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase
Observational
Started
2023-12-31
Last updated
2026-05-28
Condition(s) studied
Bacterial Infections
Investigational drug(s) / intervention(s)
β-lactams
β-lactams: Participants receiving β-lactams were included.
Study summary
Patients may benefit from the personalized β-lactams dosing strategy based on pharmacokinetics. The objective of this study is to retrospectively review, prospective observe and analyze the clinical outcomes of patients with liver cirrhosis, and to build a population pharmacokinetics model in the population mentioned above.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
Age over 18 years Chinese patient: male or female Liver cirrhosis Diagnosed as bacterial infection Treated by β-lactams Serum concentration determined during therapy
Exclusion Criteria:
Duration of β-lactams treatment less than 48 hours Patients renal or liver function not tested before treatment started Using more than two kinds of β-lactams
Primary outcome measure(s)
Mortality — January 2018-December 2026 30-day mortality and 90-day mortality
Serum concentrations — January 2018-December 2026 Serum concentrations of β-lactams
Trial sites (1)
Facility
City
Region
Status
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing
Jiangsu
Recruiting
More The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.